The 2nd Annual Pharma Pricing , Reimbrusement & Market Access 2016 is a conference that covers topics such as:
- EU and US policy challenges for market : Stepping ahead
- Preparing best market access strategy
- Current future - Challenges opportunities in pharma pricing, reimbursement market
- Unrivalled opportunity to expose and the market access challenges facing the industry
- Measurement strategies through to in-depth knowledge regarding payer formulary coverage trends
- Improving patient and market through the development of targeted value propositions, comprehensive contract assessment
- Payers perspective
- How can payers and industry work together to that innovative and valuable treatments make it to the market?
- Creating a robust patient services and reimbursement program for biosimilar products
- Advocating and collaborating with payers for value in a new era
- How price affects market [[ access ]] and learn on how to set prices for optimal access and returns
- Prioritising Patients! - Adding value through an innovative patient-centered approach
- Evidence Generation - The strategic rigor and creativity applied to evidence generation
- New drugs are failing to reimbursement from payers/HTAs at an alarming rate, despite being approved by regulators
- Developing -sharing reimbursement models and value based pricing
- Impact of social media and digital analytics
- Explaining how to the data sources and observational research for effective safety analysis
- Patient engagement and adherence within the environment
- Accelerating new medicine introduction in developing world overcoming challenges
- Dwell ahead of regulatory developments improving strategies in a cost effective way in EU, US
The 2nd Annual Pharma Pricing , Reimbrusement & Market Access 2016 brings together senior attendees with responsibilities in:
- Reimbursement
- Pricing
- Commercial Pricing
- Market Access
- Health Economics
- Pricing Strategists
- Regulatory Affairs
- Outcomes Research
- Public Affairs
- Governmental Affairs
- Operations
- Public Policy Directors
- Regulatory bodies
- Governmental bodies
